Precipio is a healthcare biotechnology company focused on cancer diagnostics. Co. develops and sells diagnostic products, reagents and services. The first panel developed using HemeScreen technology was Co.'s Myeloproliferative Neoplasms panel. Co. has since added Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Cytopenia, and BCR-ABL panels, evolving HemeScreen into a suite of genetic diagnostic panels. Co.'s IV-Cell is a proprietary cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a media that enables simultaneous culturing of four hematopoietic cell lineages. We show 27 historical shares outstanding datapoints in our coverage of PRPO's shares outstanding history.
Understanding the changing numbers of PRPO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PRPO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PRPO by allowing them to research PRPO shares outstanding history
as well as any other stock in our coverage universe. |
Free PRPO Email Alerts:
Video: Shares Outstanding Importance
